Published

Psilocybin mushrooms for psychological and existential distress: Treatment for a patient with palliative lung cancer.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Canadian family physician Medecin de famille canadien
Date: 2022-11-01
Source: PubMed
DOI: 10.46747/cfp.6811823
PubMed: 36376043

Authors

Patchett-Marble R O'Sullivan S Tadwalkar S Hapke E

Watch author

Derived topics and classifications

psilocybin End-of-Life Distress Other

Citation graph

0 referenced DOIs found in stored source metadata. 3 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Effect of psilocybin-assisted psychotherapy on anxiety symptoms: A systematic review and meta-analysis2026-05-29 PSILOCYBIN AS AN ADJUNCTIVE TREATMENT FOR DEPRESSION AND PSYCHOLOGICAL DISTRESS IN ONCOLOGY: CURRENT EVIDENCE AND CLINICAL IMPLICATIONS2026-03-19 Psilocybin mushrooms for psychological and existential distress: Treatment for a patient with palliative lung cancer.2022-11-01

Related papers

An Exploratory Pilot Study of Palliadelic Treatment to Reduce Psychological Distress in People With Pancreatobiliary and Other Advanced Gastrointestinal CancersClinicalTrials.gov · 2026-08-19 Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring OpioidsClinicalTrials.gov · 2026-08-12 PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-10 PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical TrialClinicalTrials.gov · 2026-07-10 The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.ClinicalTrials.gov · 2026-05-08 Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)ClinicalTrials.gov · 2026-04-29 Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022.Palliative & supportive care · 2023-08-01 Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label TrialClinicalTrials.gov · 2026-06-23